# Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

> **NCT00654147** · PHASE2 · COMPLETED · sponsor: **Margaret A. Fischl, M.D.** · enrollment: 44 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir & Lopinavir/ritonavir
- **DRUG:** Raltegravir and emtricitabine/tenofovir

## Key facts

- **NCT ID:** NCT00654147
- **Lead sponsor:** Margaret A. Fischl, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654147, "Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00654147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*